The Great Body-Positivity Rug Pull: Fashion Dumps Plus-Size Models the Instant Ozempic Drops
After years of lecturing the public on beauty standards, high-fashion brands quietly purged curve models once weight-loss drugs became the new celebrity cheat code.

It turns out the fashion industry's deeply emotional commitment to "body positivity" had a shelf life, and that shelf life expired the second semaglutide hit the market. For years, prestige fashion houses lectured the public about inclusivity, plastering non-traditional models across runways from New York to Paris. But the Fall-Winter 2023 catwalks have officially wrapped, and the verdict is in: the body-positivity trend has been thoroughly discarded, replaced by a return to ultra-thin standards made easily attainable via prescription pad.
The catalyst for this sudden vibe shift is the massive influx of prescription appetite suppressants. Right now, there are five injectable weight-loss medications available in the US, plus an oral pill called Rybelsus, while the UK has approved two. This pharmaceutical boom has become Hollywood's favorite open secret. Tech billionaire Elon Musk openly tweeted about using Wegovy, and comedian Chelsea Handler admitted her anti-aging doctor essentially hands Ozempic out to anyone who asks. With thinness now just a prescription away, the high-fashion elite quickly abandoned their manufactured diversity narratives to jump back on the size-zero bandwagon.
The numbers tell a hilarious story of corporate hypocrisy. Data from fashion search engine Tagwalk shows that the number of mid- and plus-size models on the runway crashed by 24% compared to the previous season. Even better, Vogue Business reported that 95.6% of all looks presented for Fall-Winter 2023 were restricted to US sample sizes 0 to 4. Keep in mind, Plunkett Research estimated in 2015 that 68% of actual American women wear a size 14 or above. The fashion industry spent years pretending to care about representing the average woman, only to immediately pivot back to elite standards the moment the technology allowed it.
The brands that previously rode the progressive wave for easy positive press are now completely silent. Fendi and Valentino, who made waves in recent years by casting models like Paloma Elsesser and Jill Kortleve, had an obvious lack of curve models on their runways this season. Erdem, which made a big show of expanding its size options to UK 22 in 2021, also joined the purge. When journalists called them out on it, Erdem declined to comment, while Fendi and Valentino ignored the emails entirely. The virtue signaling was great for business, but apparently, actually keeping those models on the runway was too much of a commitment.
IMG model agent Mina White, who manages curve stars like Ashley Graham and Paloma Elsesser, called the season "a definitive backslide." White pointed out the sheer hypocrisy of brands using Ashley Graham for clout—inviting her to sit front row in custom looks to harvest her massive social media following—while completely shutting out curve models from the actual runway. It is the ultimate corporate move: keep the diverse models in the audience for the optics, but keep the runway strictly gatekept.
Of course, anyone paying attention knew the diversity push was always a mirage. Fashion journalist Amy Odell mocked the pearl-clutching over a "backslide," asking what exactly the industry was sliding back from. Odell rightly pointed out that average-sized women were never genuinely integrated into high fashion on a level playing field anyway. The industry merely adopted a temporary aesthetic to appease activist groups, and discarded it the moment it was no longer trendy.
Ultimately, the Fall-Winter 2023 season exposed the entire corporate diversity apparatus as a performative joke. The moment a pharmaceutical cheat code for thinness became available, the gatekeepers of high fashion immediately dropped the act and returned to their preferred aesthetic. It is a stark reminder that in the world of elite culture, trends come and go, but the commitment to superficial status symbols is permanent.
Sources: * U.S. Food and Drug Administration (FDA) - Drugs@FDA Database * National Institute for Health and Care Excellence (NICE) - Guidelines on Weight Management Medications * Plunkett Research, Ltd. - Retail and Apparel Industry Market Research


